» Articles » PMID: 36795572

Systematic Investigation of the Mechanism of Herbal Medicines for the Treatment of Prostate Cancer

Overview
Specialty Geriatrics
Date 2023 Feb 16
PMID 36795572
Authors
Affiliations
Soon will be listed here.
Abstract

Due to various unpleasant side effects and general ineffectiveness of current treatments for prostate cancer (PCa), more and more people with PCa try to look for complementary and alternative medicine such as herbal medicine. However, since herbal medicine has multi-components, multi-targets and multi-pathways features, its underlying molecular mechanism of action is not yet known and still needs to be systematically explored. Presently, a comprehensive approach consisting of bibliometric analysis, pharmacokinetic assessment, target prediction and network construction is firstly performed to obtain PCa-related herbal medicines and their corresponding candidate compounds and potential targets. Subsequently, a total of 20 overlapping genes between DEGs in PCa patients and the target genes of the PCa-related herbs, as well as five hub genes, i.e., CCNA2, CDK2, CTH, DPP4 and SRC were determined employing bioinformatics analysis. Further, the roles of these hub genes in PCa were also investigated through survival analysis and tumour immunity analysis. Moreover, to validate the reliability of the C-T interactions and to further explore the binding modes between ingredients and their targets, the molecular dynamics (MD) simulations were carried out. Finally, based on the modularization of the biological network, four signaling pathways, i.e., PI3K-Akt, MAPK, p53 and cell cycle were integrated to further analyze the therapeutic mechanism of PCa-related herbal medicine. All the results show the mechanism of action of herbal medicines on treating PCa from the molecular to systematic levels, providing a reference for the treatment of complex diseases using TCM.

Citing Articles

Identification of prognostic immune subtypes of lung squamous cell carcinoma by unsupervised consistent clustering.

Wang Y, Hou L, Yang M, Fan J, Wang Y, Sun L Medicine (Baltimore). 2023; 102(37):e35123.

PMID: 37713826 PMC: 10508570. DOI: 10.1097/MD.0000000000035123.


An In Vitro Evaluation and Network Pharmacology Analysis of Prospective Anti-Prostate Cancer Activity from .

Garcia P, Huang S, De Castro-Cruz K, Leron R, Tsai P Plants (Basel). 2023; 12(16).

PMID: 37631218 PMC: 10457999. DOI: 10.3390/plants12163006.

References
1.
Kim J, Kim J, Kim H, Park K, Harris R, Cho W . Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PLoS One. 2013; 8(11):e80391. PMC: 3829856. DOI: 10.1371/journal.pone.0080391. View

2.
Jiang S, Hu L, Wang X, Li J, Zhang Z . Neurotransmitters: emerging targets in cancer. Oncogene. 2019; 39(3):503-515. DOI: 10.1038/s41388-019-1006-0. View

3.
Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J . Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000; 89(3):589-96. View

4.
Ritchie T, Macdonald S . How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans?. Drug Discov Today. 2014; 19(4):489-95. DOI: 10.1016/j.drudis.2014.01.007. View

5.
Sfanos K, De Marzo A . Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60(1):199-215. PMC: 4029103. DOI: 10.1111/j.1365-2559.2011.04033.x. View